National Institute on Drug Abuse; Notice of Closed Meetings

 
CONTENT
Federal Register, Volume 84 Issue 242 (Tuesday, December 17, 2019)
[Federal Register Volume 84, Number 242 (Tuesday, December 17, 2019)]
[Notices]
[Page 68939]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-27102]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
    Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
    Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; PHASE I: NIDA Avant-Garde Award Program for HIV/AIDS
and Drug Use Research (DP1) (Mail) and Phase II: NIDA Avant Garde
Award Program for HIV/AIDs and Drug Use Research (DP1) (Interview).
    Date: December 18, 2019.
    Time: 8:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Courtyard by Marriott, 5520 Wisconsin Avenue, Chevy
Chase, MD 20815.
    Contact Person: Hiromi Ono, Ph.D., Scientific Review Officer,
Office of Extramural Affairs, National Institute on Drug Abuse,
National Institutes of Health, DHHS, 6001 Executive Boulevard, Room
4238, MSC 9550, Bethesda, MD 20892, 301-402-6020,
[email protected].
    This notice is being published less than 15 days prior to the
meeting due to the urgent need to meet timing limitations imposed by
the intramural research review cycle.
    Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Mechanism for Time-Sensitive Drug Abuse Research
(R21 Clinical Trial Optional).
    Date: December 20, 2019.
    Time: 1:00 p.m. to 3:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center
Building (NSC), 6001 Executive Boulevard, Rockville, MD 20852
(Telephone Conference Call).
    Contact Person: Susan O. McGuire, Ph.D., Scientific Review
Officer, Office of Extramural Affairs, National Institute on Drug
Abuse, National Institutes of Health, DHHS, 6001 Executive Blvd.,
Room 4245, Rockville, MD 20852, 301-435-1426,
[email protected].
    This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance Program Nos. 93.279, Drug
Abuse and Addiction Research Programs, National Institutes of
Health, HHS)
    Dated: December 11, 2019.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2019-27102 Filed 12-16-19; 8:45 am]
BILLING CODE 4140-01-P